

# 20<sup>th</sup> Annual **Cardiovascular Update**

 $(\boldsymbol{\Sigma})$ 

# Saturday, October 23rd, 2021

7:00 a.m. - 2:30 p.m. Intermountain Medical Center -**Doty Education Center\*** 

\*Attendees may also join virtually

## **REGISTER NOW**

### Purpose

The purpose of this activity is to update primary care providers, cardiologists, and nurses on the latest advances in relation to the diagnosis and management of cardiovascular disease. This conference is designed to provide new and important information regarding cardiovascular disease, the most common cause of morbidity and mortality in America.

## **Target Audience**

Cardiovascular Update is intended for the following professions: advanced practice providers, nurses, physicians, and other health professionals caring for cardiovascular illnesses.

#### Accreditation



Intermountain Healthcare is accredited by the Accreditation Council for ACCREDITED WITH COMMENDATION Continuing Medical

Education (ACCME) to provide continuing medical education for physicians.

## AMA PRA Credit

Intermountain Healthcare designates this live activity for a maximum of 6.0\* AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Nursing Credit**



Intermountain Healthcare is accredited as a provider of nursing continuing professional development

by the American Nurses Credentialing Center's Commission on Accreditation.

This live activity offers a maximum of 6.0\* nursing contact hours. Successful completion is attending no less than 1 full session and claiming credit only for sessions attended.

\*Credit hours are subject to change and are based on actual learning hours and at the discretion of IPCE.



# Registration

Registration is required for all attendees

#### \$50.00 - Physicians \$35.00 - All other attendees

The registration fee for this conference has been covered for all Intermountain Healthcare caregivers and affiliated partners.

#### **To learn more or register visit** https://intermountain.cloud-cme.com/2021CardiovascularUpdate





**Cancellation Policy** - Cancellation and Reimbursement Policy: Full (100%) registration reimbursement for cancellation more than 14 days prior to the beginning of the activity. Half (50%) registration reimbursement for cancellation between four (4) and fourteen (14) days prior to the beginning of the activity. No reimbursement for cancellation three (3) days or less prior to the beginning of the activity.

Exceptions - Exceptions may be allowed only under extenuating circumstances and with approval from the IPCE Director, Medical Director, and AVP for IPCE.

## Agenda

7:25 AM   W     7:30 AM   Sec     7:30 AM   Tr     7:50 AM   Ex     8:10 AM   Astronomic     8:30 AM   Patronomic	Registration and Breakfast   Nelcome and Introduction   J. Brent Muhlestein, MD   Session I   Moderator: David B. Min, MD, FACC   Troponin Elevation in Young People with Normal Coronary Arteries: Why do they happen? What does it mean? How are they treated?   Kirk U. Knowlton, MD   Evaluation and Treatment of Future Cardiovascular Risk in People Under 50 Years-old: Why? Who? When? And how?   J. Brent Muhlestein, MD   Advances in the Long-Term Management of Patients Presenting with an Acute Coronary Syndrome: How many different kinds of drugs should they receive?   Nishant K. Sekaran, MD
7:30 AM   So     7:30 AM   Th     7:50 AM   Ev     8:10 AM   A     8:30 AM   Pa	Gession I   Moderator: David B. Min, MD, FACC   Troponin Elevation in Young People with Normal Coronary Arteries: Why do they happen? What does it mean? How are they treated?   Kirk U. Knowlton, MD   Evaluation and Treatment of Future Cardiovascular Risk in People Under 50 Years-old: Why? Who? When? And how?   J. Brent Muhlestein, MD   Advances in the Long-Term Management of Patients Presenting with an Acute Coronary Syndrome: How many different kinds of drugs
7:30 AM   Tr Ki     7:50 AM   Ev     8:10 AM   A st     8:30 AM   Pa	Troponin Elevation in Young People with Normal Coronary Arteries: Why do they happen? What does it mean? How are they treated?   Kirk U. Knowlton, MD   Evaluation and Treatment of Future Cardiovascular Risk in People Under 50 Years-old: Why? Who? When? And how?   J. Brent Muhlestein, MD   Advances in the Long-Term Management of Patients Presenting with an Acute Coronary Syndrome: How many different kinds of drugs
7:30 AM   Ki     7:50 AM   Ev     8:10 AM   A     8:30 AM   Pa	Kirk U. Knowlton, MD Evaluation and Treatment of Future Cardiovascular Risk in People Under 50 Years-old: <i>Why? Who? When? And how?</i> J. Brent Muhlestein, MD Advances in the Long-Term Management of Patients Presenting with an Acute Coronary Syndrome: <i>How many different kinds of drugs</i>
8:10 AM A st 8:30 AM Pa	Advances in the Long-Term Management of Patients Presenting with an Acute Coronary Syndrome: How many different kinds of drugs
8:30 AM Pa	Advances in the Long-Term Management of Patients Presenting with an Acute Coronary Syndrome: How many different kinds of drugs
9.40 AM C	Panel Discussion
0.40 AIVI 30	Session II   Moderator: Kirk U. Knowlton, MD
8:40 AM E	Emerging ASCVD Risk Factors and Innovative Therapies   Jeffrey L. Anderson, MD
9:00 AM U	Jse of Aspirin for Cardiovascular Prevention in the 21st Century: Who? When? How much? How long?   Peter T. Hu, MD
9:20 AM A	Adults with Congenital Heart Disease: What do general cardiologists and primary care physicians need to know?   Ian M. Lindsay, MD
9:40 AM Pa	Panel Discussion
9:50 AM	Break
10:00 AM S	Session III   Moderator: Jeffrey L. Anderson, MD
10:00 AM A	A Practical Approach to the Diagnosis and Management of Hypertrophic Cardiomyopathy   Jeffrey A. Goss, MSN, FNP-C
10:20 AM U	Jpdate on the Management of Heart Failure with Reduced Ejection Fraction   Rami Alharethi, MD, FACC
10:40 AM	Pregnancy and Heart Disease: A discussion of its scope, diagnosis, evaluation, and treatment   Kismet Rasmusson, DNP, FNP, FAHA, CHFN, FHFSA
	Recent Advances in Pacemaker, Defibrillator, and Other Cardiovascular Device Therapy: Which new devices will ultimately provide significant clinical benefit?   Jeffrey Osborn, MD, FACC, CCDS
11:20 AM	Medical Management of Atrial Fibrillation: What should we try before referring someone for ablation therapy?   Jared D. Miller, MD
11:40 AM Pa	Panel Discussion
11:45 AM	Break and Box Lunch
12:30 PM S	Session IV   Moderator: J. Brent Muhlestein, MD
12:30 PM E	ECG Reading Pearls   Frank G. Yanowitz, MD
12:50 PM TI	The Comprehensive Valve Center   Brian K. Whisenant, MD
1:10 PM TI	<b>Fhoracic Surgery in the 21<sup>st</sup> Century:</b> What is its role? What is its future?   Stephen H. McKellar, MD, M.Sc.
	Asymptomatic Left Ventricular Hypertrophy: How bad is it? How is it diagnosed? Who should be screened? How should it be treated? Alpana Senapati, DO, FACC
1:50 PM H	Health and Treatment Disparities Among Various Socioeconomic Groups of Patients with Heart Disease: How bad is the problem? What can we do about it?   David B. Min, MD, FACC
2:10 PM Pa	Panel Discussion
2:30 PM	Adjorn and Program Evaluation

